Copyright WILEY-VCH Verlag GmbH & Co. KGaA, 69469 Weinheim, Germany, 2015.



## Supporting Information

for Adv. Sci., DOI: 10.1002/advs. 201500008

Far-Red/Near-Infrared Conjugated Polymer Nanoparticles for Long-Term In Situ Monitoring of Liver Tumor Growth

Jie Liu, Kai Li,\* and Bin Liu\*

Copyright WILEY-VCH Verlag GmbH & Co. KGaA, 69469 Weinheim, Germany, 2013.

### Supporting Information

# Far-Red/Near-Infrared Conjugated Polymer Nanoparticles for Long-Term In-Situ Monitoring of Liver Tumor Growth

Jie Liu, Kai Li,\* and Bin Liu\*

#### Calculation of PIDT-DBT-Tat NP concentration:

The PIDT-DBT-Tat NPs stock solution (5 mL) was freeze-dried to yield 1.2 mg of powders. As the PIDT-DBT-Tat NPs have good colloidal stability in water without precipitation, the density of the NP suspension could be estimated as  $\sim 1 \text{ g/cm}^3$ . The average size of PIDT-DBT-Tat NPs determined from TEM is  $\sim 49 \text{ nm}$ . Thus, the concentration of the PIDT-DBT-Tat NPs in stock can be calculated from the following equation:

Total number of PIDT - DBT - Tat NPs in 5 mL of suspension

 $=\frac{\text{Total Volume of PIDT - DBT - Tat NPs}}{\text{Average Volume of Each NP}} = \frac{\frac{1.2 \times 10^{-3} \text{ g}}{1 \text{ g/mL}}}{\frac{4}{3} \pi \times (24.5 \times 10^{-7})^3 \text{ mL}} = 1.9 \times 10^{13}$ 

Finally, the concentration of PIDT-DBT-Tat NPs in stock solution was calculated as

following: [PIDT - DBT - Tat NP] =  $\frac{2.3 \times 10^{13}}{6.02 \times 10^{23} \text{ mol}^{-1}}{2 \times 10^{-3} \text{ L}} = 16 \text{ nM}$ 



Scheme S1. Synthetic route towards PIDT-DBT.



**Figure S1**. Average hydrodynamic diameter change of PIDT-DBT-Tat NPs when incubating in phosphate-buffered saline at 37 °C for 14 days.



**Figure S2**. Color-coded projections of z-stacks of confocal images of HepG2 cells upon incubation with PIDT-DBT-Tat NPs overnight. ( $\lambda_{ex} = 590$  nm, 600-800 nm bandpass filter).



**Figure S3**. CLSM fluorescence/transmission overlay images of HepG2 cancer cells after incubation with 2 nM (a) PIDT-DBT-Tat NPs and (b) PIDT-DBT NPs at 37 °C for 24 h. ( $\lambda_{ex}$  = 561 nm, 710/50 nm bandpass filter).



**Figure S4.** Metabolic viability of HepG2 cells (blank) and NIH/3T3 cells (gray) after incubation with 2, 4 and 8 nM PIDT-DBT-Tat NPs for 48 h.



**Figure S5.** Metabolic viability of NIH/3T3 cells after incubation with 2, 4 and 8 nM PIDT-DBT-Tat NPs for 72 h.



**Figure S6.** Bright-field image of the liver collected from mouse transplanted with  $4 \times 10^6$  of PIDT-DBT-Tat NP-labeled HepG2 cells (left) and mouse without transplantation (right) after 42-day injection.



Figure 7. Representative *ex vivo* fluorescence images of the organ tissues collected from mouse transplanted with  $4 \times 10^6$  of PIDT-DBT-Tat NP-labeled HepG2 cells after 0 and 7 days post injection.